The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Serial MRD assessment as a surrogate for PFS in multiple myeloma
Frits van Rhee, MD, PhD, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, discusses the results of a study which used serial measurable residual disease (MRD) assessment as a surrogate for long-term progression-free survival (PFS) in patients with multiple myeloma. The study showed that patients who were persistently MRD negative in the first five years after transplant had excellent PFS, whilst patients who were persistently MRD positive were at increased risk of relapse. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
